-
Je něco špatně v tomto záznamu ?
Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents
J. Vančo, J. Gáliková, J. Hošek, Z. Dvořák, L. Paráková, Z. Trávníček,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Free Medical Journals od 2006
Public Library of Science (PLoS) od 2006
PubMed Central od 2006
Europe PubMed Central od 2006
ProQuest Central od 2006-12-01
Open Access Digital Library od 2006-01-01
Open Access Digital Library od 2006-10-01
Open Access Digital Library od 2006-01-01
Medline Complete (EBSCOhost) od 2008-01-01
Nursing & Allied Health Database (ProQuest) od 2006-12-01
Health & Medicine (ProQuest) od 2006-12-01
Public Health Database (ProQuest) od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources od 2006
Odkazy
PubMed
25333949
DOI
10.1371/journal.pone.0109901
Knihovny.cz E-zdroje
- MeSH
- antiflogistika chemie farmakologie terapeutické užití MeSH
- antitumorózní látky chemie farmakologie terapeutické užití MeSH
- edém farmakoterapie MeSH
- hepatocyty účinky léků MeSH
- hypoxanthiny chemie farmakologie terapeutické užití MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- nádorové buněčné linie MeSH
- nádory farmakoterapie MeSH
- spektroskopie infračervená s Fourierovou transformací MeSH
- zánět farmakoterapie MeSH
- zlato chemie farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022955
- 003
- CZ-PrNML
- 005
- 20150709122653.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0109901 $2 doi
- 035 __
- $a (PubMed)25333949
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vančo, Ján $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 245 10
- $a Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents / $c J. Vančo, J. Gáliková, J. Hošek, Z. Dvořák, L. Paráková, Z. Trávníček,
- 520 9_
- $a The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x chemie $x farmakologie $x terapeutické užití $7 D000893
- 650 _2
- $a antitumorózní látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a edém $x farmakoterapie $7 D004487
- 650 _2
- $a zlato $x chemie $x farmakologie $x terapeutické užití $7 D006046
- 650 _2
- $a hepatocyty $x účinky léků $7 D022781
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoxanthiny $x chemie $x farmakologie $x terapeutické užití $7 D007042
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $7 D017550
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gáliková, Jana $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Hošek, Jan $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Dvořák, Zdeněk $u Regional Centre of Advanced Technologies and Materials & Department of Cell Biology and Genetics, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Paráková, Lenka $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Trávníček, Zdeněk $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 10 (2014), s. e109901
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25333949 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150709122712 $b ABA008
- 999 __
- $a ok $b bmc $g 1083294 $s 905948
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 10 $d e109901 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20150709